Last updated: 2026-09-05 02:06:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Tenax Therapeutics, Inc. (TENX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.94, with a market capitalisation of $69.23M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.31 to $19.40. This page covers its latest market performance, valuation, price trends and company information.
$69.23M | |
$1.82 | |
$152,320.00 | |
$1.31 | |
$1.78 | |
4.04M | |
-- | |
-- | |
$19.40 | |
$1.31 | |
-- | |
-- |
Tenax Therapeutics, Inc. (TENX) last closed at $1.78 as of 2026-09-05 00:00:00, unchanged from the previous close of $1.78.
During the latest regular trading session, TENX traded between $1.31 and $152,320.00, with a volume of 4.04M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Tenax Therapeutics, Inc. (TENX) moved from $2.11 to $1.94, representing a decline of 7.93% ($0.17).
The stock traded between $1.80 and $1.95 during the period. The latest price is near the upper end of the 7-day range, indicating strong downward.
The average daily volume was 7.05 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 3.5%
TENX is currently trading at $1.94, placing it 3.5% of the way from its 52-week low of $1.31 to its 52-week high of $19.40. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 16 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Tenax Therapeutics, Inc. (TENX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.